• Lysosomal Exocytosis in MPS IVA Cartilage Pathology

  2026-08-31

  A 2026 study in Disease Models & Mechanisms links enhanced lysosomal exocytosis with altered protease activity, glycosaminoglycan distribution, and TGFβ/BMP signaling in galns-mutant zebrafish cartilage. The work moves beyond a storage-only model of mucopolysaccharidosis type IVA and provides a framework for testing how lysosome-mediated membrane trafficking contributes to skeletal disease.

• 25-Hydroxycholesterol Reprograms TAM AMPK Signaling

  2026-08-31

  Xiao et al. identify CH25H and lysosome-accumulated 25-hydroxycholesterol as an immunometabolic checkpoint that activates AMPKα and reinforces STAT6-dependent ARG1 production in tumor-associated macrophages. The study connects sterol compartmentalization with macrophage-mediated immune suppression and shows why CH25H targeting may improve T-cell surveillance and anti-PD-1 responses.

• HotStart™ 2X Green qPCR Master Mix for Dosage Assays

  2026-08-30

  HotStart 2X Green qPCR Master Mix enables specific SYBR Green qPCR for dosage-sensitive genotyping. Learn how to translate low-coverage sequencing and non-invasive sampling into reproducible cephalopod assays.

• Protease Inhibitor Cocktail for Protein Workflows

  2026-08-29

  Protect labile proteins during extraction, immunoprecipitation, Western blotting, and kinase assays with an EDTA-free, broad-spectrum formulation. This guide connects practical sample-preservation workflows with biomarker studies such as melatonin-loaded hydrogel research while clearly separating product-supported use from experimental recommendations.

• Ridaforolimus: From mTOR Signals to Senolytic Assays

  2026-08-28

  Ridaforolimus and Deforolimus provide a precise mTOR perturbation for cancer and senescence-aware research. This guide connects pathway readouts, apoptosis assays, angiogenesis inhibition, and machine-learning-informed senolytic screening without confusing cytostasis with selective senescent-cell elimination.

• LSE mRNA Delivery for Durable T Cell Immunity

  2026-08-28

  The 2026 Cell Reports Medicine study developed a lipid nanoparticle-stabilized emulsion (LSE) that redirects mRNA delivery toward antigen-presenting cells and regulates the timing and location of antigen expression. In mice, this design produced durable, diverse T cell responses and showed activity in vaccination and tumor models, providing a framework for improving cellular immunity beyond conventional LNP formulations.

• Tacrine Hydrochloride Hydrate: Mechanism & Research

  2026-08-27

  Tacrine hydrochloride hydrate, also known as Tetrahydroaminacrine, is a research-grade cholinesterase inhibitor for studying acetylcholine neurotransmission enhancement. Its benchmark AChE activity supports Alzheimer’s disease research, while historical hepatotoxicity limits direct clinical interpretation.

• Large-Scale Gastruloid Arrays for Phenotype Screening

  2026-08-27

  Jan and colleagues developed an indexed magnetic microraft array that enables image-based analysis and automated sorting of individual human gastruloids at scale. The platform distinguished euploid and aneuploid developmental phenotypes while linking reduced DNA density with altered NOG and KRT7 expression, creating a practical framework for single-gastruloid screening.

• Exendin-4 Workflows for Reliable Cell Assays

  2026-08-26

  Learn how Exendin-4 (SKU A3408) can be integrated into beta-cell, viability, proliferation, and cytotoxicity workflows with stronger control of dosing, handling, and interpretation. This scenario-based guide connects product specifications with GLP-1 receptor biology and practical assay design.

• 3X (DYKDDDDK) Peptide: Uses and Workflow

  2026-08-26

  The 3X (DYKDDDDK) Peptide is a hydrophilic, tandem FLAG epitope reagent for antibody-based detection, affinity workflows, and structural biology. The 3X FLAG peptide is reported to dissolve at concentrations of at least 25 mg/ml in defined TBS and to show calcium-dependent antibody binding, making buffer and metal controls important.

• Irinotecan (A5133): Reliable Cell Assay Workflows

  2026-08-25

  This scenario-based guide explains how Irinotecan (SKU A5133) can support reproducible viability, cytotoxicity, and colorectal cancer research workflows. It covers prodrug activation, assay design, solubility management, IC50 interpretation, translational limitations, and practical supplier-selection criteria.

• CP-673451: Translational PDGFR Strategy in Glioma

  2026-08-25

  A thought-leadership framework for using CP-673451 to connect PDGFR biology, ATRX-defined glioma vulnerability, angiogenesis assays, and xenograft translation without confusing pathway engagement with clinical efficacy.

• ATRX-Deficient Glioma and PDGFR Inhibitor Sensitivity

  2026-08-24

  Pladevall-Morera and colleagues show that ATRX-deficient high-grade glioma cells are unusually sensitive to several receptor tyrosine kinase and PDGFR inhibitors. The study also identifies enhanced toxicity when these agents are combined with temozolomide, supporting ATRX status as an important variable in therapeutic studies and clinical-trial interpretation.

• BCL-XL inhibitor A-1155463: Workflow Guide

  2026-08-24

  Build more informative apoptosis, resistance, and tumor-model experiments with a selective BCL-XL inhibitor. This practical guide covers dosing design, dependency validation, assay controls, formulation, and interpretation for solid-tumor and hematological malignancies research.

• Irinotecan: Reliable Assays in Cancer Research

  2026-08-23

  A scenario-based guide to using Irinotecan (SKU A5133) in cell viability, proliferation, and cytotoxicity workflows. It addresses prodrug activation, solubility, protocol design, interpretation, and practical supplier selection for reproducible colorectal cancer research.

7964 records 1/531 page Next 12345 下5页 Last page